AbbVie Buy Hold or Sell Recommendation

<div class='circular--portrait' style='background:#CD0D74;color: white;font-size:3em;padding-top: 40px;;'>ABB</div>
ABBV -- USA Stock  

Fiscal Quarter End: March 31, 2020  

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding AbbVie is 'Hold'. Macroaxis provides AbbVie buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding AbbVie positions. The advice algorithm takes into account all of AbbVie available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from AbbVie buy-and-hold perspective. Please continue to AbbVie Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Sell AbbVieBuy AbbVie


Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

For the selected time horizon AbbVie has a risk adjusted performance of (0.019309), jensen alpha of (0.016307), total risk alpha of 0.149, sortino ratio of 0.0 and treynor ratio of (0.24)
Macroaxis provides buy, hold, or sell suggestion on AbbVie to complement and cross-verify current analyst consensus on AbbVie. Our buy, hold, or sell recommendation engine determines the organization potential to grow exclusively from the perspective of investors current risk tolerance and investing horizon. To make sure AbbVie is not overpriced, please confirm all AbbVie fundamentals, including its Shares Outstanding, Net Income, Price to Earnings To Growth, as well as the relationship between Price to Book and Current Ratio . Given that AbbVie has Price to Earning of 16.74 , we suggest you validate AbbVie market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.

AbbVie Trading Alerts and Improvement Suggestions

AbbVie generates negative expected return over the last 30 days
Over 77.0% of the company shares are held by institutions such as insurance companies
On January 14, 2020 AbbVie paid $ 1.18 per share dividend to its current shareholders
Latest headline from MacroaxisInsider: Bona fide gift to Richard Gonzalez of tradable shares of AbbVie subject to Section 16

AbbVie current analysts recommendations

Target Median Price100.50
Target Mean Price101.08
Recommendation Mean2.20
Target High Price130.00
Number Of Analyst Opinions12
Target Low Price84.00

AbbVie Returns Distribution Density

Mean Return0.03Value At Risk2.22
Potential Upside2.50Standard Deviation1.54
 Return Density 

Institutional Investors

Security TypeSharesValue
Vanguard Group IncCommon Shares122.6 M10.9 B
Blackrock IncCommon Shares98.6 M8.7 B
Capital Research Global InvestorsCommon Shares86.6 M7.7 B
State Street CorpCommon Shares68.8 M6.1 B
Fmr LlcCommon Shares40.2 M3.6 B
Price T Rowe Associates IncCommon Shares28.1 M2.5 B
Geode Capital Management LlcCommon Shares24.4 M2.2 B

AbbVie Greeks

Alpha over DOW
Beta against DOW=0.16
Overall volatility
Information ratio =0.07

AbbVie Volatility Alert

AbbVie exhibits very low volatility with skewness of 0.65 and kurtosis of 2.61. However, we advise investors to further study AbbVie technical indicators to make sure all market info is available and is reliable.
 Better Than Average     
 Worse Than Average Compare AbbVie to competition

AbbVie Fundamental Vs Peers

FundamentalsAbbViePeer Average
Return On Equity(1.88) (0.31) 
Return On Asset11.53 (0.14) 
Profit Margin23.69 (1.27) 
Operating Margin47.24 (5.51) 
Current Valuation159.08 B16.62 B
Shares Outstanding1.48 B571.82 M
Shares Owned by Insiders0.09 10.09 
Shares Owned by Institutions77.25 39.21 
Number of Shares Shorted74.74 M4.71 M
Price to Earning16.74 28.72 
Price to Book43.51 9.51 
Price to Sales3.93 11.42 
Revenue33.27 B9.43 B
Gross Profit25.83 B27.38 B
EBITDA15.71 B3.9 B
Net Income7.84 B570.98 M
Cash and Equivalents39.92 B2.7 B
Cash per Share26.99 5.01 
Total Debt67.09 B5.32 B
Debt to Equity9.53 48.70 
Current Ratio3.18 2.16 
Book Value Per Share(5.53) 1.93 K
Cash Flow from Operations13.32 B971.22 M
Short Ratio8.40 4.00 
Earnings Per Share5.28 3.12 
Price to Earnings To Growth2.51 4.89 
Number of Employees30 K18.84 K
Market Capitalization130.77 B19.03 B
Total Asset53.05 B29.47 B
Retained Earnings3.73 B9.33 B
Working Capital5.42 B1.48 B
Current Asset16.31 B9.34 B
   Bona fide gift to Richard Gonzalez of tradable shares of AbbVie subject to Section 16 [view details]